David C. Swinney

5.6k total citations · 1 hit paper
64 papers, 4.0k citations indexed

About

David C. Swinney is a scholar working on Molecular Biology, Pharmacology and Computational Theory and Mathematics. According to data from OpenAlex, David C. Swinney has authored 64 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 17 papers in Pharmacology and 10 papers in Computational Theory and Mathematics. Recurrent topics in David C. Swinney's work include Pharmacogenetics and Drug Metabolism (16 papers), Computational Drug Discovery Methods (10 papers) and Receptor Mechanisms and Signaling (10 papers). David C. Swinney is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), Computational Drug Discovery Methods (10 papers) and Receptor Mechanisms and Signaling (10 papers). David C. Swinney collaborates with scholars based in United States, Switzerland and Belgium. David C. Swinney's co-authors include On‐Yee So, D Kertesz, Jim Barnett, Thomas K. H. Chang, Wayne Levin, Dene E. Ryan, Keith A. M. Walker, Chakkodabylu S. Ramesha, Janet Nicol and Janet Dean Fodor and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Hepatology.

In The Last Decade

David C. Swinney

63 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

How were new medicines discovered?

2011 1.2k citations David C. Swinney et al. profile →

Peers

Countries citing papers authored by David C. Swinney

Since Specialization

Citations

This map shows the geographic impact of David C. Swinney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David C. Swinney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David C. Swinney more than expected).

Fields of papers citing papers by David C. Swinney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David C. Swinney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David C. Swinney. The network helps show where David C. Swinney may publish in the future.

Co-authorship network of co-authors of David C. Swinney

This figure shows the co-authorship network connecting the top 25 collaborators of David C. Swinney. A scholar is included among the top collaborators of David C. Swinney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David C. Swinney. David C. Swinney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phenotypic Drug Discovery 2020 ·David C. Swinney, (unknown)	5
2	Development of a Bioluminescent High-Throughput Screening Assay for Nicotinamide Mononucleotide Adenylyltransferase (NMNAT) 2019 ·SLAS DISCOVERY ·Brad A. Haubrich, C S Ramesha, David C. Swinney	9
3	Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates 2016 ·Current Drug Discovery Technologies ·Brad A. Haubrich, David C. Swinney	19
4	A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β 2016 ·PLoS neglected tropical diseases ·(unknown), Brad A. Haubrich, Shuangluo Xia, C S Ramesha, (unknown), (unknown), Kojo Mensa‐Wilmot, David C. Swinney	16
5	Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib 2016 ·Archives of Biochemistry and Biophysics ·Mohammad Hekmat-Nejad, (unknown), (unknown), Alan K. Kutach, David E. Shaw, Eric Fang, David C. Swinney	2
6	Phenotypic vs. Target-Based Drug Discovery for First-in-Class Medicines 2013 ·Clinical Pharmacology & Therapeutics ·David C. Swinney	276
7	Transcriptomic analysis of the woodchuck model of chronic hepatitis B 2012 ·Hepatology ·Simon P. Fletcher, Daniel J. Chin, Yongmei Ji, Leonardo Iniguez, Bruce E. Taillon, David C. Swinney, Palanikumar Ravindran, Donavan T. Cheng, Hans Bitter, Uri Lopatin, Han Ma, Klaus Klumpp, Stephan Menne	78
8	Characterization of the Elongation Complex of Dengue Virus RNA Polymerase 2010 ·Journal of Biological Chemistry ·Zhinan Jin, Jérôme Deval, Kenneth A. Johnson, David C. Swinney	42
9	Essential Role of the N-terminal Domain in the Regulation of RIG-I ATPase Activity 2008 ·Journal of Biological Chemistry ·Peter Gee, Pong Kian Chua, (unknown), Klaus Klumpp, Isabel Nájera, David C. Swinney, Jérôme Deval	53
10	Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase 2007 ·Journal of Biological Chemistry ·(unknown), D. Grünberger, Hoangdung Ho, Stan Tsing, David E. Shaw, Simon J. Craddock Lee, Jim Barnett, Ronald J. Hill, David C. Swinney, J. Michael Bradshaw	37
11	Bi‐substrate Kinetic Analysis of an E3‐Ligase–Dependent Ubiquitylation Reaction 2005 ·Methods in enzymology on CD-ROM/Methods in enzymology ·David C. Swinney, Michael J. Rose, (unknown), (unknown), (unknown), (unknown)	2
12	Targeting protein ubiquitination for drug discovery. What is in the drug discovery toolbox? 2001 ·Drug Discovery Today ·David C. Swinney	12
13	Differential Allosteric Regulation of Prostaglandin H Synthase 1 and 2 by Arachidonic Acid 1997 ·Journal of Biological Chemistry ·David C. Swinney, (unknown), Jim Barnett, Chakkodabylu S. Ramesha	94
14	Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterol-lowering activity 1995 ·Biochemical Pharmacology ·Pamela M. Burton, David C. Swinney, (unknown), (unknown), (unknown), (unknown), (unknown), Keith A. M. Walker, (unknown), (unknown), (unknown), L Tökès	27
15	Cloning and functional expression of the cDNA encoding rat lanosterol 14-α demethylase 1995 ·Gene ·David L. Sloane, On‐Yee So, (unknown), (unknown), (unknown), Kurt Jarnagin, David C. Swinney	19
16	Androgen Formation by Cytochrome P450 CYP17. Solvent Isotope Effect and pL Studies Suggest a Role for Protons in the Regulation of Oxene versus Peroxide Chemistry 1994 ·Biochemistry ·David C. Swinney, (unknown)	52
17	Selective inhibition of mammalian lanosterol 14.alpha.-demethylase: a possible strategy for cholesterol lowering 1993 ·Journal of Medicinal Chemistry ·(unknown), D Kertesz, (unknown), David C. Swinney, Pamela Berry, (unknown), (unknown), (unknown), (unknown)	27
18	Stereoisomers of ketoconazole: preparation and biological activity 1992 ·Journal of Medicinal Chemistry ·(unknown), D Kertesz, Keith A. M. Walker, David C. Swinney	116
19	A novel rat hepatic clofibrate-inducible cytochrome P450 that is not a lauric acid hydroxylase 1991 ·Biochemical Pharmacology ·David C. Swinney, (unknown), Richard Freedman	6
20	Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat. 1990 ·Drug Metabolism and Disposition ·David C. Swinney	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact